Quick Answer: EU cosmetic compliance has no universal processing time or standard CPNP approval period. A product can be placed on the market only after the applicable safety assessment, Product Information File (PIF), labelling and CPNP notification are ready under Regulation (EC) No 1223/2009. Most project time is spent preparing and checking product evidence; a special rule requires advance notification for certain nanomaterials. Build a timeline from verified product-specific tasks, not a promised number of days.
Is there a fixed EU cosmetic approval timeline?
No. Ordinary cosmetics are not generally pre-approved through CPNP. The European Commission CPNP page describes a notification portal, not a waiting period that certifies safety or approval. Article 13 of Regulation (EC) No 1223/2009 requires the Responsible Person (RP) to submit specified information before placing the product on the market. A completed portal entry is only one milestone.
The clock for a real launch depends on whether the final formula, packaging, label artwork and safety evidence already exist and are suitable for the intended EU sale. Ask the EU-established RP and qualified safety assessor to assess the evidence before promising a launch date to a distributor.
| Workstream | What must be ready | Typical cause of delay |
|---|---|---|
| Product classification and final scope | Cosmetic status, intended use, formula and target markets | A drug-like claim or changed intended use |
| Safety assessment | Qualified assessor and signed CPSR for final product | Incomplete ingredient, exposure or test evidence |
| Product Information File | Article 11 contents held by the RP | Missing GMP or manufacturing records |
| Label and claims | Final artwork with required information and supported claims | Translation, warnings or unsupported claims |
| CPNP notification | Article 13 data submitted before placing on market | Mismatch between notification and final product |
| Release decision | RP verifies all applicable obligations are met | Formula, pack or claim change after sign-off |
A practical sequence for planning launch
1. Freeze the product identity
Document the final formulation and INCI information, intended users, use pattern, packaging, name and claims. A sample formula is not enough if the production formula or pack will differ. Decide which legal entity will act as the EU-established RP. For non-EU brands, clarify the importer or written RP designation under Article 4.
2. Identify evidence gaps
The safety assessor evaluates the finished product with the information required by Annex I of the Regulation. Depending on the product, existing supplier data may need to be supplemented with stability, microbiological, compatibility or other relevant evidence. The Commission’s CPSR guidance explains the report structure. Do not invent a standard test package or test duration for every product.
3. Complete CPSR and PIF
The RP must ensure a safety assessment has been performed before placing the product on the market and keep the PIF available at the address indicated on the label. The PIF includes more than the CPSR: the product description, manufacturing method and GMP statement, claims substantiation where justified and relevant animal-testing data are also addressed by Article 11. The RP should have a controlled process for updates.
4. Finalise artwork and notification
Article 19 governs required label particulars, while Article 20 concerns claims. Verify language requirements for the destination market and check that the CPNP record reflects the final product. CPNP notification is free of charge, but a service provider may charge for preparation or acting as RP. A notification confirmation is not regulatory approval.
5. Release only the verified version
Before first EU supply, compare the production batch specification, final pack, artwork, CPSR, PIF and CPNP entry. If a material change occurs, return to the assessor and RP to decide what must be updated. Keep a change log rather than treating a previous report as permanent approval.
When can a special advance-notification rule affect timing?
For certain cosmetic products containing nanomaterials, Article 16 adds a separate notification to the European Commission six months before placing on the market, subject to the regulation’s stated exceptions. The Commission’s nanomaterials guidance describes this route. This is not a general six-month rule for all cosmetics. The RP must assess whether the product and ingredient fall within Article 16 and whether an exception applies.
| Scenario | Planning implication | Who confirms it |
|---|---|---|
| Standard cosmetic with complete data | Use a task-based schedule; no generic CPNP approval wait | RP and assessor |
| Product with missing stability or microbiology evidence | Include time to generate and review the required evidence | Assessor, laboratory and manufacturer |
| Product with altered claims or packaging | Recheck safety, claims, label and notification data | RP and assessor |
| Potential Article 16 nanomaterial product | Investigate the separate advance-notification rule early | RP with relevant technical expertise |
| Several EU destination markets | Plan artwork and language review by market | RP and local distribution team |
How should a brand build a credible schedule?
Use a dated dependency list rather than a single “EU compliance time” number. For each deliverable, record the owner, input required, evidence version, review gate and contingency. The longest unresolved dependency controls the realistic release date. Ask a provider which work can run in parallel and which must wait for the final formulation or finished-pack data. Avoid paying for a guaranteed fast-track approval that the law does not describe.
Read our CPNP, CPSR and PIF comparison, EU claims guide and ingredient review guide to identify linked tasks. A cost workstream should be built from the same evidence gaps.
What can a manufacturer provide?
A cosmetic OEM/ODM manufacturer can provide formula/INCI information under an agreed disclosure process, specifications, COAs, relevant SDSs, manufacturing and GMP records, batch data, stability and microbiological reports where available, and packaging-compatibility information. The brand and RP must confirm whether those documents are sufficient for the EU product. The manufacturer cannot promise a CPNP “approval date” or sign the safety assessment unless separately qualified and appointed for that role.
Frequently asked questions
How long does CPNP approval take?
CPNP is a notification portal, not an ordinary approval procedure. There is no general EU-wide CPNP approval countdown for cosmetic products.
Can I notify before the final formula is ready?
A launch plan may be prepared early, but the required notification and safety documentation must accurately describe the final product before market placement.
Does an existing supplier CPSR save time?
It may provide useful evidence only if a qualified assessor and RP confirm it covers the actual formula, packaging, use and marketed version.
Does the six-month nanomaterial rule apply to every cosmetic?
No. Article 16 applies to specified nanomaterial cases subject to exceptions; it is not a general EU cosmetic waiting period.
Official sources and review
Regulation (EC) No 1223/2009; European Commission CPNP; Commission CPSR guidance; European Commission nanomaterials. Last reviewed: 28 September 2026. Editorial preparation: MOOYAM cosmetic compliance content team. This article explains regulatory steps and project planning, not a legal opinion or guaranteed schedule.
For documentation and manufacturing planning tied to a specific formula, contact MOOYAM. MOOYAM provides cosmetic OEM/ODM manufacturing and technical-documentation support for international beauty brands; the EU RP and safety assessor remain responsible for their statutory decisions.
Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or a qualified compliance professional before placing cosmetic products on the market.